Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bullishHigh impact
Esc
Oura logo illustration
Photo: Reuters / Dado Ruvic

Oura IPO Targets $15.6B Valuation on Nasdaq Debut

SEC EDGAR2 min read6 sources

Why is Oura IPO priced at $15.6 billion?

Oura (OURA) launched its IPO roadshow on Monday at $40–$44 a share, targeting a $15.6B Nasdaq valuation backed by $400M in cornerstone orders from Eli Lilly and Dragoneer.

Key numbers

IPO Valuation (fully diluted)$15.6B+42% vs $11B last private round
IPO Raise (50M shares at $40–$44)up to $2.2B~$533M in primary proceeds to Oura
Revenue (9M ended Jun 30, 2026)$1.21B+74% YoY from $697.6M
Paid Members5.0M+100% YoY from 2.5M
Gross Margin (9M FY2026)55%+4pp vs 51% prior year
Cornerstone Interest$400MEli Lilly $100M + Dragoneer $300M

What happened

Oura (OURA) launched its IPO roadshow on Monday at $40–$44 a share, targeting a $15.6B Nasdaq valuation backed by $400M in cornerstone orders from Eli Lilly and Dragoneer. The Finnish smart ring maker is selling 50 million shares — 73% from existing holders — aiming to raise up to $2.2B in total. Revenue for the nine months ended June 30, 2026 hit $1.21B, up 74% year on year, as paid members doubled to 5 million across 56 countries. Oura plans to list on Nasdaq under the ticker OURA during the week of September 28.

Why it matters

Oura is one of the few profitable consumer health companies going public right now, making it a notable test of investor appetite for health-data wearables. Eli Lilly's $100M commitment signals that pharmaceutical companies view health rings as clinical-grade data tools, not just fitness gadgets, which could open a new revenue stream beyond retail consumers. With roughly 80% of global smart ring sales and 85% subscriber retention, Oura enters public life with a dominant market position that rivals like Samsung Galaxy Ring have so far been unable to dent.

Who this affects

Marketbullish
High impact
Nasdaq gains a pure-play consumer health wearables stock.
Companybullish
High impact
Oura raises ~$533M in primary capital at $15.6B valuation.
Competitorsbearish
Medium impact
Garmin and Samsung Galaxy Ring face a better-capitalized rival.
Industrybullish
Medium impact
IPO validates smart ring as standalone consumer health category.

Oura vs Garmin, Samsung Galaxy Ring

OuraOURA:NASDAQ$15.6B (IPO)$1.4B+74%55%
GarminGRMN:NYSE$55.9B$7.9B+14%~57%
Samsung Galaxy Ring005930.KSSamsung: $250B+———

As of 2026-09-25

How we got here

  1. Oura files S-1 with SEC showing $1.21B revenue and 74% YoY growth.

  2. Oura announces IPO launch; Eli Lilly flags $100M cornerstone interest.

  3. Roadshow begins; 50M shares offered at $40–$44, $15.6B target valuation.

  4. Expected IPO pricing week; Oura to list on Nasdaq as OURA.

What to watch

  • IPO pricing and opening-day trade vs $44 top of range on Nasdaq.2026-09-30
  • First earnings report revealing FY2026 full-year revenue and guidance.Q4 2026
  • Eli Lilly partnership expansion and pharmaceutical use of Oura health data.Q4 2026

Educational content only. Not investment advice.

More briefsAll briefs →